|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.10 EUR | +1.02% |
|
+6.48% | +13.74% |
| 15/01 | Bayer Upgraded to Buy as mwb Notes 'Improving Medium-term Risk-Reward' | MT |
| 15/01 | European Midday Briefing : Shares Rise; Gold and Oil Fall on Easing U.S.-Iran Tensions | DJ |
Business description: Bayer AG
- agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.6%);
- other (0.7%).
Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).
Number of employees: 88,502
Sales by Activity: Bayer AG
| Fiscal Period: December | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) |
|---|---|---|---|---|---|
Crop Science | 1.88TCr | 2.02TCr | 2.52TCr | 2.33TCr | 2.23TCr |
Pharmaceuticals | 1.73TCr | 1.84TCr | 1.93TCr | 1.81TCr | 1.82TCr |
Consumer Health | 505.4Cr | 529.3Cr | 608Cr | 603.4Cr | 587.5Cr |
All Other | 37Cr | 20Cr | 22Cr | 24Cr | 33Cr |
Enabling Functions and Consolidation | -16Cr | -50L | -10L | -3.6Cr | -7.2Cr |
Geographical breakdown of sales: Bayer AG
| Fiscal Period: December | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) |
|---|---|---|---|---|---|
United States | 1.29TCr | 1.34TCr | 1.57TCr | 1.46TCr | 1.48TCr |
Europe / Middle East / Africa (Excl. Germany & Switzerland) | 1TCr | 1.06TCr | 1.14TCr | 1.11TCr | 1.1TCr |
Asia / Pacific (Excl.China) | 478.4Cr | 499.3Cr | 519.2Cr | 474.5Cr | 447.1Cr |
Brazil | 299.4Cr | 347.6Cr | 532.2Cr | 496.7Cr | 431.7Cr |
Latin America (Excl. Brazil) | 290.6Cr | 315.6Cr | 396.6Cr | 396.1Cr | 376.1Cr |
China | 348.3Cr | 385.6Cr | 425.9Cr | 362.4Cr | 360Cr |
Germany | 236.1Cr | 254.5Cr | 247.7Cr | 244.8Cr | 241Cr |
North America (Excl.United States) | 146.7Cr | 155.5Cr | 188.6Cr | 166.7Cr | 168.1Cr |
Switzerland | 50Cr | 54Cr | 60Cr | 57Cr | 58Cr |
Executive Committee: Bayer AG
| Manager | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 59 | 01/06/2023 |
| Director of Finance/CFO | 56 | 01/06/2018 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/02/2021 |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/06/2020 |
Thomas Kornek
IRC | Investor Relations Contact | - | 01/11/2021 |
Composition of the Board of Directors: Bayer AG
| Director | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 69 | 01/04/2002 |
André van Broich
BRD | Director/Board Member | 55 | 01/04/2012 |
| Director/Board Member | 66 | 01/04/2022 | |
Frank Löllgen
BRD | Director/Board Member | 64 | 01/11/2015 |
Colleen Goggins
BRD | Director/Board Member | 70 | 01/04/2017 |
Heike Hausfeld
BRD | Director/Board Member | 60 | 01/04/2017 |
| Chairman | 68 | 28/04/2020 | |
Ertharin Cousin
BRD | Director/Board Member | 67 | 01/10/2019 |
| Director/Board Member | 68 | 28/04/2020 | |
Alberto Weisser
BRD | Director/Board Member | 69 | 01/04/2021 |
Holdings: Bayer AG
| Name | Equities | % | Valuation |
|---|---|---|---|
BAYER CROPSCIENCE LIMITED 71.43% | 3,21,02,999 | 71.43% | 1 629 M $ |
| 52,85,489 | 7.71% | 65 M $ | |
| 1,26,75,838 | 14.5% | 13 M $ | |
| 40,50,997 | 10.79% | 7 M $ | |
SENTI BIOSCIENCES, INC. 12.03% | 31,62,157 | 12.03% | 3 M $ |
PYXIS ONCOLOGY, INC. 4.4% | 27,42,338 | 4.4% | 3 M $ |
BOUNDLESS BIO, INC. 7.22% | 16,15,201 | 7.22% | 2 M $ |
AZITRA, INC. 0.07% | 7,256 | 0.07% | 1 923 $ |
Company details: Bayer AG
Group companies: Bayer AG
| Name | Category and Sector |
|---|---|
Bayer CropScience, Inc. (Philippines)
 Bayer CropScience, Inc. (Philippines) Manufactures agricultural chemicals | |
Bayer 04 Leverkusen Fußball GmbH
 Bayer 04 Leverkusen Fußball GmbH Movies/EntertainmentConsumer Services Operates as a sports clubs |
Movies/Entertainment
|
Bayer 04 Leverkusen Fußball GmbH
Bayer 04 Leverkusen Fußball GmbH Movies/EntertainmentConsumer Services Operates as a sports clubs |
Movies/Entertainment
|
Elanco Animal Health GmbH
 Elanco Animal Health GmbH Engages in researching and developing of antimicrobials, parasiticides and care products | |
Elanco Animal Health GmbH
Elanco Animal Health GmbH Engages in researching and developing of antimicrobials, parasiticides and care products |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.02% | +6.48% | +103.06% | -26.68% | 4.8TCr | |
| -3.76% | -4.81% | +38.33% | +185.65% | 92TCr | |
| +0.47% | +6.72% | +51.46% | +26.60% | 53TCr | |
| -2.32% | -3.29% | +26.50% | +41.11% | 38TCr | |
| +0.46% | +1.86% | +30.01% | +18.51% | 37TCr | |
| -2.23% | -1.06% | +31.72% | +20.33% | 29TCr | |
| -1.36% | +0.63% | +26.39% | +35.48% | 27TCr | |
| -0.04% | -0.02% | +10.87% | -1.14% | 28TCr | |
| -3.45% | -1.39% | -39.64% | -22.02% | 25TCr | |
| +0.32% | -0.02% | +22.72% | +21.46% | 18TCr | |
| Average | -1.09% | +0.51% | +30.14% | +29.93% | 35.23TCr | |
| Weighted average by Cap. | -1.63% | -0.47% | +29.04% | +62.63% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
- Company Bayer AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition